Introduction
============

In a previous JCMR paper entitled, \"MRI in Patients with Pacemakers and ICDs: Defining the Issues\", the authors discussed controversies related to imaging patients with cardiac pacemakers and implantable cardiac defibrillators (ICDs) which had not been specifically designed for the magnetic resonance imaging (MRI) environment \[[@B1]\]. Since that time, technological advances have led to the first generation of MR conditional cardiac pacemakers, allowing for greater patient management options as well as a new set of issues and controversies. One paradoxical effect created by this burst of medical innovation is the potential limitation of application of a technology due to the presence of another technology in the same patient. Because a significant percentage of patients with cardiac devices may potentially have indications for MRI during their lifetime \[[@B2]\], application of MR conditional devices is important to allowing patients access to MR scanning under well defined conditions. The engineering and implementation of these devices requires an understanding of: 1) all device/MRI interactions, 2) design issues to minimize or eliminate these interactions, and 3) patient management decision-making algorithms for their safe application. This review will discuss the development and implementation of MR conditional cardiac pacemakers and issues related to future design and implementation of other cardiac devices.

Studies of MRI/Cardiac Pacemaker Interactions
---------------------------------------------

Previous studies have identified issues laying the groundwork for design improvements to engineer so-called MR conditional devices with the MRI environment under strict conditions for the patient, the device, and MRI parameters. The term, \"MR conditional\" refers to an item that has been demonstrated to pose no known hazards in a specified MR environment with specified conditions of use \[[@B3]\]. \"Field\" conditions that define the MR environment include static magnetic field strength, spatial gradient magnetic field, dB/dt (time rate of change of the magnetic field), radio frequency (RF) fields, and specific absorption rate (SAR). Additional conditions, including specific configurations of the item (e.g., the routing of leads used for a neurostimulation system), may be required.

The medical literature from the pre-MR conditional cardiac device era arises from: 1) *in vitro*investigations of cardiac pacemakers and implantable cardiac defibrillators (ICDs), 2) isolated case reports, 3) retrospective series of patients with devices unintentionally or intentionally placed in the MRI environment and 4) prospective studies with defined patient and MR conditions \[[@B4]-[@B69]\]. Additionally, a physician initiated prospective multicenter site registry of pacemakers and ICDs using 1.5 Tesla non-thoracic scans has been initiated (The MagnaSafe Registry) \[[@B70],[@B71]\]. Table [1](#T1){ref-type="table"} summarizes *in vivo*human data related to both pacemakers and ICDs. These data demonstrated certain adverse interactions of cardiac pacemakers and ICDs in the MRI environment and provided variable results regarding safety with prospective studies under defined conditions. These data led to controversy regarding study under well-defined conditions in cases where the use of MRI was essential to patient management versus the need for devices engineered to be MR conditional \[[@B1],[@B72]-[@B79]\]. The issues raised by these data, however, were essential to prospective multicenter human studies completed \[[@B80]-[@B82]\], ongoing \[[@B83]\], and planned \[[@B84]\] to assess the safety and efficacy of the first generation of MR conditional cardiac pacemakers.

###### 

MRI in Patients with Pacemakers and ICDs.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                    Device              Year   Patient/Studies Report Type     MRI\                              Findings
                                                                                       Condition                         
  ------------------------- ------------------- ------ ------------------------------- --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Iberer \[[@B8]\]          PPM                 1987   1/1 Case                                                          No adverse effect

                                                                                                                         

  Alonga \[[@B11]\]         PPM                 1989   1/1 Case Intentional            1.5 T\                            No adverse effect
                                                                                       Brain                             

                                                                                                                         

  Inbar \[[@B12]\]          PPM                 1993   1/1 Case Intentional            1.5 T\                            No adverse effect
                                                                                       Brain                             

                                                                                                                         

  Gimbel \[[@B15]\]         PPM                 1996   5/5 Retrospective Intentional   0.35-1.5T\                        Two second pause
                                                                                       Cardiac, Brain, C-Spine           

                                                                                                                         

  Garcia-Boloa \[[@B16]\]   PPM                 1998   1/2 Case Intentional            1.0 T\                            No adverse effect
                                                                                       Brain                             

                                                                                                                         

  Fontaine \[[@B98]\]       PPM                 1998   1/1 Case Intentional            1.5 T\                            Rapid pacing
                                                                                       Brain, C-Spine                    

                                                                                                                         

  Sommer \[[@B143]\]        PPM                 1998   18/18 Prospective               0.5 T\                            Asynchronous mode due to activation of the reed switch in all patients
                                                                                       Brain, Cardiac, Vascular          

                                                                                                                         

  Sommer \[[@B18]\]         PPM                 2000   45/51 Prospective               0.5 T\                            No adverse effect
                                                                                       Multiple                          

                                                                                                                         

  Valhaus \[[@B20]\]        PPM                 2001   32/34 Prospective               0.5T\                             Decrease in battery voltage recovered at 3 months
                                                                                       Multiple                          

                                                                                                                         

  Martin \[[@B29]\]         PPM                 2004   54/62 Prospective               1.5 T\                            Significant change in pacing threshold in 9.4% of leads, and 1.9% of leads requiring an increase in programmed output.
                                                                                       Multiple                          

                                                                                                                         

  Del Ojo \[[@B32]\]        PPM                 2005   13/13 Prospective               2.0 T\                            No adverse effect.
                                                                                       Multiple                          

                                                                                                                         

  Rozner \[[@B41]\]         PPM                 2005   2/2 Case Intentional            1.5 T\                            Transient change to ERI in 1 patient.
                                                                                       Thorax, Lumbar                    

                                                                                                                         

  Gimbel \[[@B33]\]         PPM                 2005   10/11 Prospective               1.5 T\                            Small variances in pacing threshold were seen in four patients.
                                                                                       Brain\                            
                                                                                       C-Spine                           

                                                                                                                         

  Sommer \[[@B50]\]         PPM                 2006   115/82 Prospective              1.5 T\                            Significant increase in pacing threshold, decreased lead impedance, and decrease in battery voltage. No inhibition of pacing or arrhythmias and no leads which required an increase in pacing output.
                                                                                       Extra-thoracic                    

                                                                                                                         

  Heatlie \[[@B52]\]        PPM                 2007   5/6 Prospective                 0.5 T Cardiac                     Pacing at maximum voltage at a fixed rate of 100 beats/minute in one patient.

                                                                                                                         

  Anfinsen \[[@B22]\]       ICD                 2002   1/1 Case Inadvertent            0.5 T\                            Inappropriate sensing, battery voltage transient change to EOL.
                                                                                       Brain                             

                                                                                                                         

  Fiek \[[@B28]\]           ICD                 2004   1/1 Case Inadvert               0.5 T\                            Unable to communicate with device.
                                                                                       Brain                             

                                                                                                                         

  Coman \[[@B30]\]          ICD                 2004   11/11 Prospective               1.5 T\                            Brief asymptomatic pause in 1 patient.\
                                                                                       Cardiac, Vascular, General        Unable to communicate with device in 1 patient.

                                                                                                                         

  Gimbel \[[@B34]\]         ICD                 2005   7/8 Prospective                 1.5 T\                            \"Power on reset\" electrical reset requiring reprogramming in 1 patient.
                                                                                       Brain, L-Spine                    

                                                                                                                         

  Roguin \[[@B39]\]         ICD                 2005   1/1 Case Intentional            1.5 T Cardiac                     No adverse effect.

                                                                                                                         

  Wollmann \[[@B44]\]       ICD                 2005   1/3 Case Intentional            1.5 T\                            No adverse effect.
                                                                                       Brain                             

                                                                                                                         

  Naehle \[[@B46]\]         ICD                 2006   1/1 Case Intentional            1.5 T\                            No adverse effect.
                                                                                       Brain                             

                                                                                                                         

  Nazarian \[[@B47]\]       PPM 31\             2006   68/55 Prospective               1.5 T                             No adverse effect.
                            ICD 24                                                                                       

                                                                                                                         

  Nemec \[[@B48]\]          ICD                 2006   1/1 Case Unintentional          Not specified\                    Noise detected as ventricular tachycardia and ventricular fibrillation, with no therapy presumably due to magnetic mode activation. Asynchronous pacing due to noise-reversal mode.
                                                                                       Brain                             

                                                                                                                         

  Sardanelli \[[@B144]\]    PPM                 2006   1/1 Case Intentional            1.5 T\                            No adverse effect.
                                                                                       Breast                            

                                                                                                                         

  Mollerus \[[@B56]\]       PPM 32\             2008   37/40 Prospective               1.5 T\                            No adverse effect.\
                            ICD 5                                                      Truncal, non-truncal              No changes in cardiac troponin-I

                                                                                                                         

  Naehle \[[@B57]\]         PPM                 2008   44/51 Prospective               3.0 T\                            No adverse effect.\
                                                                                       Brain                             No changes in cardiac troponin-I\
                                                                                                                         (Use of transmit-receive head coil)

                                                                                                                         

  Gimbel \[[@B59]\]         PPM                 2009   1/1 Case Intentional            2.0 T\                            Asystole
                                                                                       Brain                             

                                                                                                                         

  Goldsher \[[@B60]\]       PPM                 2009   1/1 Case Intentional            1.5 T\                            No adverse effect.\
                                                                                       Cervical                          Scan one day after implant\
                                                                                                                         Pacemaker dependent

                                                                                                                         

  Mollerus \[[@B61]\]       PPM 46\             2009   52/59 Prospective               1.5 Truncal, non-truncal          MRI-related ectopy 7 pt
                            ICD 6                                                                                        

                                                                                                                         

  Naehle \[[@B62]\]         PPM                 2009   47/171 Case Intentional         1.5 T\                            Statistically significant but clinically irrelevant change in pacing capture threshold and battery voltage.\
                                                                                       General                           2 or more serial scans.

                                                                                                                         

  Pulver \[[@B64]\]         PPM                 2009   8/11 Prospective                1.5 T\                            No adverse effect.\
                                                                                       Cardiac, non-cardiac              Congenital heart disease with 9 epicardial leads.

                                                                                                                         

  Strach \[[@B67]\]         PPM                 2010   114/114 Prospective             0.2 T\                            No adverse effect
                                                                                       General                           

                                                                                                                         

  Millar \[[@B66]\]         PPM                 2010   1/1                             1.5 T\                            No adverse effects
                                                                                       Brain C-spine                     

                                                                                                                         

  Burke \[[@B117]\]         PPM 24\             2010   38/92 Prospective               1.5 T\                            No adverse effects\
                            ICD 10\                                                    Brain, Spine, Pelvis, Extremity   No changes defibrillation threshold (ICD)
                            CRT ICD 4                                                                                    

                                                                                                                         

  Buendia \[[@B100]\]       PPM 28\             2010   33/33 Prospective               1.5 T\                            Temporary communication failure in two patients.\
                            ICD 5                                                      Cardiac Brain, Spine,\            Sensing errors during imaging in two patients.,\
                                                                                       Abdominal, Extremity              Safety signal generated in one pacemaker at the maximum magnetic resonance frequency and output level.

                                                                                                                         

  Cohen \[[@B70]\]          PPM 74\             2010   105/105 Prospective             1.5 T                             No deaths, device failures, genrerator/lead replacements, loss of capture, or electrical reset.\
                            ICD 31                                                                                       Decrease in battery voltage of ≥ 0.04 V in 2%\
                                                                                                                         Lead impedance change ≥ 50 Ohms in 3%\
                                                                                                                         High voltage impedance change ≥ 3 Ohms in 10%\
                                                                                                                         Decrease in R wave amplitude in 2%\
                                                                                                                         Pacing threshold increase of ≥ 0.5 V at 0.4 ms in 1% of leads

                                                                                                                         

  Wilkoff \[[@B81]\]        MR ConditionalPPM   2011   226/226 Prospective             1.5 T\                            No adverse effect
                                                                                       Brain and lumbar                  

                                                                                                                         

  Quarta \[[@B140]\]        MR ConditionalPPM   2011   1/1 Prospective                 1.5 T\                            No adverse effect
                                                                                       Brain, Cardiac                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adapted and Updated from Shinbane et al. 2007. \[[@B1]\]

Case = case report, EOL = end-of-life, ERI = elective-replacement indices; ICD-implantable cardiac defibrillator; PPM = pacemaker; T = Tesla,.

In a randomized, unblinded, two arm study of patients who met standard criteria for dual chamber pacing (484 enrolled, 464 with successful implant, 258 randomized to a single non-medically indicated MRI scan and 206 randomized to a control group) there were no significant changes in pacing parameters (sensing, threshold, or impedance change) compared to controls \[[@B81]\]. Both pacemaker-dependent and non-pacemaker dependent patients were studied, with MR scanning in the asynchronous mode (n = 158), and no pacing (n = 67) with a continuous stable rhythm during scanning. Although pacemaker dependence was not assessed at the time of scanning, 16 MR scanned and 11 control patients had no underlying intrinsic ventricular rhythm at the pre-9- to 12-week assessment. There were no reported complications through the one month visit including arrhythmias, electrical reset, inhibition of generator output, or adverse sensations.

The safe implementation of new MR conditional technologies requires a detailed understanding of the MR nomenclature as it relates to specific patient and scanning conditions \[[@B3]\]. The American Society of Testing Materials (ASTM) designates devices as MR safe, MR conditional, and MR unsafe \[[@B85]\]. As an MR safe device would require nonmetallic, non-conducting materials and systems with no known hazards in all MR environments, it would be impossible to develop a pacing system with this designation. As MR conditional refers to devices which pose no known hazards when applied with specific conditions and a specific MR environment, the approval of a device requires strict definition of these conditions. Recently, the United States Food and Drug Administration (FDA) approved an MR conditional pacing system, the Revo™ MRI SureScan^®^Pacing System (Medtronic, Inc., Minneapolis, MN) \[[@B81]\]. Outside of the United States \[Biotronik (Berlin, Germany), Medtronic, Inc. (Minneapolis, MN), and St. Jude Medical (St. Paul, MN), there are commercially available MR conditional cardiac pacemakers \[[@B86],[@B87]\]. Importantly, each MR conditional system is composed of an MR conditional pulse generator, MR conditional leads, and MR conditional programming (Table [2](#T2){ref-type="table"}). These and other manufacturers have systems in development and testing. Each system has its own individual conditions which must be adhered to. Therefore, knowledge of the individual system conditions is essential for the safe performance of MR scanning. In reference to scanner type, the currently approved field strength is 1.5 Tesla, and scanning is not approved for field strengths above or below this strength. Due to rapid advances in technology and clinical studies, the medical staff involved in this field must continually update their knowledge base related to MR conditional cardiac devices. This includes information on changes in devices and MR conditions as specified by the approving agency in the country where the device is being implanted and patient scanned.

###### 

MRI Patient and Scanner Conditions for Clinically Released MR Conditional Systems in the United States or the European Community.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  System                                           Medtronic EnRhythm MRI™ SureScan™ Pacing System                                                                                                                                    St. Jude Medical™ MR Conditional Pacing System                                                                                                                                               Biotronik ProMRI™ MR Conditional Pacing System
  ------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Approval**                                     United State (FDA appoval)\                                                                                                                                                        European Community (CE approval)                                                                                                                                                             European Community (CE approval)
                                                   European Community (CE approval)                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Studies**                                      Wilcoff et al. \[[@B81]\]\                                                                                                                                                         Accent MRI Study \[[@B145]\]. (In process)                                                                                                                                                   
                                                   Forleo et al. \[[@B82]\]\                                                                                                                                                                                                                                                                                                                                                       
                                                   Advisa MRI Study \[[@B83]\]. (In process)                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Implant site**                                 Left or right pectoral region                                                                                                                                                      Left or right pectoral region                                                                                                                                                                Chest area.\
                                                                                                                                                                                                                                                                                                                                                                                                                                   Patient\'s height at least 1.4 meters

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Limitations related to other devices/leads**   No active or abandoned medical devices, leads, lead extenders or adaptors                                                                                                          No abandoned cardiac hardware including leads, lead extenders, or lead adaptors                                                                                                              No other pacemakers or ICDs, leads no longer in use, lead adapters, lead extension

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Implant timing prior to MRI**                  At least six weeks                                                                                                                                                                 Stable pacing capture threshold values                                                                                                                                                       At least 6 weeks.

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Acceptable lead parameters for MRI**           Capture thresholds of ≤ 2.0 V at a pulse width of 0.4 ms\                                                                                                                          Capture threshold values of ≤ 2.5 V at 0.5. ms pulse width\                                                                                                                                  Capture threshold ≤ 2.0 V at 0.4 ms pulse width\
                                                   Impedance of ≥ 200 and ≤ 1500 Ohms\                                                                                                                                                Lead impedance measurements within the programmed lead impedance limits\                                                                                                                     Lead impedance is between 200 and 1500 Ohms •\
                                                   No diaphragmatic pacing at 5.0 V at a pulse width of 1.0 ms                                                                                                                        No diaphragmatic stimulation at a pacing output of 5.0 V or 7.5 V and at a pulse width of 1.0 ms if device will be programmed to an asynchronous pacing mode when MRI Settings are enabled   Battery charging status: at least 30%

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Programming for MRI**                          MR conditional programming modes                                                                                                                                                   MR conditional programming modes                                                                                                                                                             MR conditional programming modes

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Device Identifiers**                           Pulse generator radiopaque marking with a unique symbol and three letter code\                                                                                                     A radio-opaque MRI symbol is present on all implanted St. Jude Medical™ MR Conditional pacing system components\                                                                             Pulse generator radiopaque marking.\
                                                   Unique radiopaque lead helix design                                                                                                                                                Radiopaque MR Conditional lead marker                                                                                                                                                        No lead radiopaque identifier

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Scanner**                                      1.5 Tesla cylindrical bore MR system                                                                                                                                               1.5 Tesla horizontal closed bore MR system                                                                                                                                                   1.5 Tesla cylindrical bore MR system

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Landmark isocenter of RF coil**                United States: Superior to C1 or inferior to T12\                                                                                                                                  Contraindication to use of local transmit-only coils or local transmit and receive coils placed directly over the pacing system                                                              Maximum allowed positioning mark for the isocenter starting from the foot at the hip bone level. and maximum allowed positioning mark for the isocenter from the top of the skull at the level of the eyes).
                                                   Ensura MRI™ SureScan™ Pacing System and Advisa DR MRI™ SureScan™ pacemaker labeling has no restrictions on chest scans outside the United States                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Patient Positioning**                          Contraindication to lateral decubitus patient positioning                                                                                                                          Must not be positioned on side                                                                                                                                                               Dorsal position only.

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Scanner Mode**                                 Scanner in\' the normal operating mode (defined as the mode of operation of the MR system in which none of the outputs have a value that cause physiological stress to patients)   Scanner in the normal operating mode or First Level Controlled operating mode                                                                                                                The overall MR scanning time accumulated from the imaging times as displayed by the MRI scanner must not exceed 30 minutes\
                                                                                                                                                                                                                                                                                                                                                                                                                                   The total accumulated length of examination for the pacing system must be below 10 hours

                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Radiofrequency Energy**                        Maximum gradient slew rate ≤ 200 T/m/s per axis\                                                                                                                                   Maximum gradient slew rate ≤ 200 T/m/s per axis\                                                                                                                                             Maximum gradient slew rate ≤ 200 T/m/s per axis\
                                                   Whole body specific absorption rate (SAR) levels ≤ 2 W/kg\                                                                                                                         Whole body specific absorption rate (SAR) ≤ 4.0 W/kg\                                                                                                                                        Whole body specific absorption rate (SAR) ≤ 2.0 W/kg\
                                                   Head SAR ≤ 3.2 W/kg                                                                                                                                                                Head SAR ≤ 3.2 W/kg                                                                                                                                                                          Head SAR ≤ 3.2 W/kg
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Design and Engineering Issues
-----------------------------

A cardiac pacemaker system is composed of leads and a pulse generator composed of connectors, circuitry, and a battery. In regard to the MRI environment, factors related to magnetic field interactions and transfer of electromagnetic energy must be taken into account with the specific design of these components.

Pacemaker Design and Magnetic Force Issues
------------------------------------------

The presence of ferromagnetic content in the strong static and gradient magnetic fields of the MR system can lead to movement and vibration of the cardiac device. These forces are directly related to the amount and shape of the ferromagnetic content, the location of this content in relation to the MR system, and the strength of the static magnetic field \[[@B88]\]. Although excessive magnetic field interactions can theoretically cause device movement, prospective data on both \"standard\" and MR conditional pacemakers at 1.5 Tesla did not demonstrate significant clinical effects \[[@B32],[@B57],[@B81]\].

One pacemaker design mechanism to limit magnetic field interactions is minimization of ferromagnetic content of the generator. Reduction of ferromagnetic content can be achieved through use of non-ferromagnetic conductive substances in the pacemaker generator. The leads are made of nonmagnetic materials. There are significant limitations on the choice of non-ferromagnetic materials, as the materials must be appropriately conductive, durable, and biocompatible.

An MRI-related factor which can decrease magnetic field interactions is the use of a lower magnetic field strength. Another factor is the maximization of the distance between the cardiac device and scanner during imaging. An example of this is a dedicated extremity MR system to scan the patient \[[@B17]\]. The further development of specialized scanners that utilize these factors may be useful \[[@B17],[@B89],[@B90]\].

An additional magnetic field interaction is related to the effect of a static magnetic field of the MR system on the pacemaker reed switch. The reed switch is a feature in many pacemakers designed to program a pacemaker by means of a magnet placed over the device. Reed switch magnet responses in pacemakers may cause changes to a continuous asynchronous pacing mode (DOO or VOO) in order to avoid electromagnetic interactions during such procedures as surgery with the use of electrocautery (i.e., which generates electromagnetic interference) \[[@B91]\]. Reed switch activation associated with exposure to an MR system may not be predictable. It may vary with strength of the static magnetic field and with orientation of the reed switch to the magnetic field \[[@B14],[@B26],[@B36]\]. Given this unpredictability, an MR conditional pacemaker has been designed with replacement of the reed switch with a solid state Hall sensor \[[@B80],[@B81]\]. The Hall sensor has a more predictable behavior when exposed to magnetic fields. Another pacemaker has a magnet detect sensor that prevents problems with the reed switch \[[@B92]\]. Future design related to magnetic field will need to also address higher field strengths \[[@B57],[@B59],[@B93]\].

Pacemaker Design and Electromagnetic Energy Conduction Issues
-------------------------------------------------------------

Electromagnetic energy from the MR scanner can conduct through the pacing system or cause electrical interference with components of the system. Sources of this electromagnetic energy include the pulsed radiofrequency energy from a head or body coil and the time varying magnetic fields used by the MR system for spatial localization of signals. The transfer of radiofrequency energy to heat and electrical energy is dependent on factors including: 1) the pulse sequence parameters, 2) the whole body averaged and local specific absorption rates (SAR) associated with a given sequence, 3) spatial relation and orientation of the anatomy to the transmit RF coil, and 4) lead factors (composition, length, geometry, configuration, and orientation) \[[@B51],[@B54],[@B55],[@B63],[@B94]-[@B97]\].

Pacing leads can potentially act as antennae for electromagnetic energy impulses \[[@B27],[@B98]\]. The transfer of electromagnetic energy can lead to myocardial electrical stimulation, tissue destruction at the lead tip/endocardial interface, pain, and damage to the pulse generator circuitry/battery. This may produce adverse effects on sensing, pacing thresholds, and lead impedances, and can cause inappropriate pacing acceleration or inhibition, and battery depletion \[[@B4],[@B6],[@B7],[@B9],[@B20],[@B29],[@B31],[@B33],[@B36],[@B41],[@B43],[@B50],[@B52],[@B61],[@B62],[@B98]-[@B100]\] In a recent investigation by Wilkoff et al. \[[@B81]\] on an MR conditional pacing system, these adverse effects were not observed. Pacing thresholds did not change significantly between patients with the device who were scanned and those who served as control patients.

Factors involved in pacemaker lead design relate to avoidance of the resonant frequency as well as the lead length, configuration, and position. As a lead can act as a receiver of electromagnetic impulses, avoiding the resonant frequency of a lead is of extreme importance. A resonant lead length has been associated with a greater heating effect \[[@B101]\].

A pacemaker lead is composed of an outer and inner insulation and an outer and inner lead coil. The lead coil is arranged in a configuration to maximize energy efficient conduction while maintaining flexibility, durability and minimization of lead diameter. The inner coil is made of filaments wound in a three-dimensional relationship coiled with a certain pitch. This has implications for MRI-related energy conduction based on the resonant frequency of the lead \[[@B35]\].

An example of lead design changes in an MR conditional lead is a lead modification due to a change in the pitch of the inner coil \[[@B102]\]. The inner coil was designed with a decreased number of coiled filars, increasing the number of winding turns and, therefore, increasing the lead inductance. This geometry limits the radiofrequencies that can conduct through the lead filaments. The decrease in the number of filars required an increase in the filar diameter to increase the strength of the lead. Additionally, a lead tip coating was used with a substance that decreased polarization. As unipolar pacing is more susceptible to the MRI environment, a bipolar lead design was used so that the generator was not essential to the pacing circuit \[[@B21],[@B43]\].

Measurements of lead heating with in vitro models can be challenging \[[@B103]\]. In models, many factors affect heating at the lead tip including length and the geometric structure of the lead, phantom shape, and position of the radiofrequency coil. Closer proximity of leads to the edge of the phantom and to the edge of the coil caused greatest heating \[[@B55]\]. Another phantom study at 1.5 T demonstrated greatest heating with the torso centered along the superior-inferior direction of the transmit coil \[[@B97]\]. In vitro study of lead design has demonstrated increased heating with increased lead insulation thickness and uncoiled leads of 25-50 cm length \[[@B104]\]. This study demonstrated decreased heating with increased lead impedance and winding configuration with reversed winding segments.

Abandoned leads can also conduct radiofrequency energy. In an *in vivo*study of clinical lead lengths (40-60 cm), abandoned leads demonstrated greater lead tip heating in comparison to leads attached to pulse generators \[[@B68]\]. Therefore, no additional abandoned leads should be present \[[@B81]\]. As interactions can occur with abandoned leads, special attention to the patient\'s device history regarding abandoned leads is important.

Circuitry filters to impede or limit the transfer of certain frequencies, circuits that divert and dissipate energy, and generator shielding can also be important to design in order to avoid or minimize the transfer of electromagnetic energy. Of note, retained epicardial wires cut short at the skin level from previous cardiothoracic surgery procedures do not appear to be associated with serious MRI-related issues \[[@B105],[@B106]\].

Application of Defined MR Conditions
------------------------------------

Of paramount importance to the implementation of these new technologies is the education and training of the medical community involved in care of cardiac device patients who are undergoing MR scans. The goals of education are to provide optimal patient care and efficient patient flow in the MR center. This includes understanding of the pacemaker programming to an MR conditional mode. The design of the programming hardware and software must include features to inactivate sensing, internal assessment of system integrity, and clear programming return to pre-scan values.

The decision as to the appropriate pacing mode during MR scanning requires arrhythmia expertise. Understanding of the patient\'s initial indication for the device, arrhythmia history, and underlying rhythm/pacemaker dependence are important aspects of clinical information. The underlying sinus rate, AV nodal conduction, and presence rate and location of escape rhythms are important in making decisions as to the appropriate programming mode (Figure [1](#F1){ref-type="fig"}). Additionally, many pacemakers have logs listing the percentage of time that a patient is paced in the atrium or ventricle. One needs to interpret this data though in regard to the programmed pacing rate and programmed AV intervals, as the patient may have a regular rhythm under these programmed parameters. As predicting bradyarrhythmic or tachyarrhythmic events on a beat by beat basis is challenging, even when the appropriate mode is chosen based on past history, meticulous and continuous monitoring of the patient\'s heart rate and rhythm is required while the patient is programmed in the appropriate MR conditional mode. Asynchronous pacing is used with scanning a pacemaker dependent patient. In those patients with an underlying rhythm who are not bradycardic, a ventricular rate competing with the asynchronous pacing could lead to pacing during ventricular repolarization, potentially causing an R on T phenomenon leading to life threatening ventricular arrhythmias \[[@B36],[@B107],[@B108]\].

![**Intracardiac Electrocardiograms Demonstrating Pacemaker Dependence**. Upper Panel: The presenting rhythm is sinus rhythm at 80 beats per minute with ventricular pacing. Middle Panel: Asynchronous dual chamber pacing. Lower Panel: The underlying rhythm is sinus with complete heart block with ventricular pacing at 35 beats per minute. This patient has complete heart block with no ventricular escape at 35 beats per minute.](1532-429X-13-63-1){#F1}

The pacemaker programmer device must be outside of the MR scanner room. Device programming immediately before entering the MRI environment and device interrogation and reprogramming immediately after removal from the MRI environment can limit the amount of time that the patient is in the MR conditional mode. Before MRI scanning, the initial programming mode is stored, so that devices can be programmed back to the original settings.

Even with advances in use of MR conditional ECG monitoring equipment, the MRI environment causes artifacts in the recordings. Therefore, meticulous attention to ECG electrode pad positioning and skin prep must be performed to assure adequate monitoring \[[@B109],[@B110]\]. Visual and verbal assessment of the patient\'s level of consciousness, blood pressure and pulse oximetry monitoring provide additional mechanisms to alert the MRI technologists, nurses, and/or physician of any unusual sensations or issues. The presence of healthcare professionals who have completed training in the programming and scanning of the specific MR conditional device and availability of a defibrillator (albeit, to be used outside of the MR system room), are essential.

Although scanning a patient with an MR conditional device following the strict patient and MRI-related conditions appears straightforward, issues that impact patients with pre-existing devices remain complex. Until MR conditional devices are the routine platform for all of these devices, there will still be challenging decisions regarding using MRI in patients with pre-existing devices where imaging is required to diagnose and manage a potentially life threatening scenario, such as a central nervous system tumor, cord compression, stroke or hemorrhage \[[@B44],[@B47],[@B60]\]. The previous database for non-MR conditional devices is, therefore, still important in individualizing the risk:benefit ratio in these challenging circumstances \[[@B1],[@B69],[@B111],[@B112]\].

As the MR conditional system was designed for the pulse generator to be used only with the MR conditional leads, an MR conditional generator cannot be simply attached to pre-existing leads and retain MR conditional labeling. A decision would need to be made as to whether to scan the patient with their pre-existing system or whether to extract the pacing system and place an MR conditional cardiac pacemaker. Because there can be significant complications with system extraction and replacement, including vascular damage, cardiac perforation, infection, etc., the risk:benefit ratio of these options needs to be carefully decided by physicians with expertise in these areas \[[@B113]\]. Additional questions will relate to the best approach to generator change-outs in patients at elective replacement who will likely require MRI procedures in the future, recognizing that change to a MR conditional system requires explant of the entire system including leads and implant of new system.

Special Design Issues Related to ICDs
-------------------------------------

Data related to the use of MRI in patients with ICDs are limited with variable results, with some isolated reports demonstrating no significant effects while others described issues with ability to communicate with the ICD post scan, sensing of electromagnetic noise, and changes in battery voltage \[[@B22],[@B28],[@B34],[@B39],[@B44],[@B46]-[@B48],[@B53],[@B56],[@B61],[@B88],[@B100]\]. ICDs possess additional complexity compared to pacemakers due to the larger size and complexity of leads, circuitry related to arrhythmia detection and treatment, and capacitors for cardioversion and defibrillation \[[@B114]-[@B116]\].

The increased ferromagnetic content of ICDs compared to pacemakers will require special attention to design and study of magnetic field interaction issues. Magnetic field interactions with the magnet response of many ICDs may cause inactivation of arrhythmia detection leading to inhibition of ICD therapies. Reliable magnetic responses in the MRI environment will need to be assessed as well as programming to ensure that ICD antitachycardia pacing, cardioversion and defibrillation therapies are not attempted by the ICD while the patient is in the MR scanner.

With ICDs, transmitted electromagnetic currents associated with MRI could potentially trigger tachyarrhythmia detection, if detection is not programmed to the \"off\" mode before MRI. It is unclear, though, whether ICD capacitors can charge in the presence of the MR system\'s powerful static magnetic field \[[@B46]\]. ICD programming in the MRI environment will require reliable and clear mechanisms to deactivate sensing modes to avoid inappropriate sensing of radiofrequency energy, as well as programming of pacing modes along the lines of MR conditional pacemakers.

Special intra-scan issues related to ICDs stem from the fact that these patients typically have an underlying cardiac substrate predisposing them to potentially life threatening ventricular arrhythmias. The arrhythmia history regarding the frequency of arrhythmias and overall cardiovascular patient stability are important, and these patients require meticulous monitoring while therapies are inactivated during an MRI examination. Programming design will also need to provide straight forward mechanisms to activate and confirm the original programming post-scan. The need for post-scanning ICD defibrillation threshold testing is another issue which warrants further assessment \[[@B117]\].

Future Issues Related to the Spectrum of Cardiac Devices and Scanners
---------------------------------------------------------------------

Given the expanding role of biomedical devices in diagnosis and treatment of medical conditions, design and engineering will play an important role in the future of many technologies as they relate to the MRI environment \[[@B118]\]. The gamut of cardiac devices includes atrial/biventricular and biventricular pacemakers and ICDs, subcutaneous ICDs, arrhythmia monitors and implantable physiologic measurement devices, and temporary pacing systems. Each of these technologies has a different lead number, shape, size and location, as well as generator function, size, and geometry. Additionally, neuromodulation devices (including those devices used for vagus nerve stimulation, deep brain stimulation, spinal cord stimulation, and stimulation of other organs) derived from cardiac pacemaker technologies are being implanted in patients with potential problematic MRI interactions and, thus, the need for further design modifications \[[@B119]-[@B125]\].

MRI is also utilized to direct such procedures as cardiac vascular/valvular interventions, cardiac electrophysiology procedures, biopsy, surgical, ablative, cryogenic, directed chemotherapeutic procedures, and neuromodulation treatments \[[@B126]-[@B137]\]. Biomedical device design changes will be necessary to allow the use of these technologies when they are MR-guided to avoid device/imaging interactions \[[@B138],[@B139]\].

Design and engineering will not only need to take into account safety, but also: 1) the effect of MR conditional devices on diagnostic quality of the MR images, 2) application to cardiac imaging, 3) cost effectiveness and 4) impact on overall patient care. As MRI artifacts principally affect the local region of implanted devices, for pacemakers, ICDS, and other cardiac biomedical devices, artifact issues will be most important to cardiovascular and thoracic imaging \[[@B31],[@B39],[@B64],[@B140]\]. The currently released MR conditional pacemaker in the United States requires specific landmarking steps be taken to acquire cardiac images, although not in Europe. In the European Community, the Biotronik system has a scan exclusion zone with the maximum allowed positioning mark for the isocenter starting from the foot at the hip bone level and the maximum allowed positioning mark for the isocenter from the top of the skull at the level of the eyes, while the St. Jude system specifies contraindication only to the transmit-only or local transmit and receive coils directly over the pacing system \[[@B81],[@B86],[@B87]\].

Both isocenter and artifact issues are important to the future of cardiac imaging using MR conditional pacemakers. Regarding artifacts from the pacer components, there is no easy solution, as gradient echo and steady state free precession images may be significantly distorted by regional changes in magnetic field homogeneity. For MRI examinations involving the region of the thorax, issues related to artifacts (i.e., both signal loss and image distortion) will obviously have great importance. In one study of patients with cardiac pacemakers or ICDs, 93% of thoracic scans were diagnostically acceptable \[[@B47]\].

Regarding chest imaging, issues of stress testing necessitate further investigation. The underlying lack of chronotropic competence in many patients with pacemakers and well as current programming algorithms with fixed pacing rates or programmed off for MR conditional pacemakers could be challenging for studies which require an elevation to 85% of the maximum of heart rate with stress. Coronary vasodilator stress would appear to be the most practical approach, but require further study. As with many new technologies, decisions regarding implementation in populations, cost, reimbursement and continued future design systems will need to be investigated (Table [3](#T3){ref-type="table"}).

###### 

Issues Raised by the Advent of MR Conditional Cardiac Devices Which Require Further Study.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient Selection            Who should receive MR conditional devices?\
                               Should MR conditional devices become the standard platform or used only in those patients with a higher risk of needing MR scanning in the future?\
                               Who is at highest risk of needing future MR scanning?
  ---------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Medical**\                 What are the most efficient and safest algorithms for coordination of medical staff from multiple disciplines (radiology, cardiology, cardiac electrophysiology, pacemaker technicians, MR technicians), in assessing, monitoring, and scanning patients?
  **Coordination**             

                               

  **Study Type and Quality**   What is the spectrum of MR studies that can be performed with MR conditional cardiac devices regarding study types, imaging sequences, and the use of stress testing?\
                               What is the impact of MR conditional devices on image quality?\
                               How can cardiac MR imaging be performed with MR conditional devices?

                               

  **Impact on Care**           Does use of MR conditional cardiac devices improve the quality of patient care?\
                               What is the optimal approach to MR scanning in a patient with a non-MR conditional device in place regarding risks of extraction and replacement versus scanning with the implanted system?

                               

  **Cost**                     What is the impact of implantation of MR conditional devices on device cost, physician and technologist time and cost for assessment and monitoring of patients?\
                               How should reimbursement and reimbursement codes for system placement and peri-scanning monitoring/device assessment be determined?
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Conclusions
===========

The advancement of MR conditional technology has led to greater options for patient management and has also resulted in greater complexity of clinical issues. The current MR conditional pacing technology provides definite solutions to some specific issues related to MR scanning. Future design, engineering, testing, and implementation of systems will need to focus on a goal of broadening these applications to further decreasing the barriers to scanning patients with cardiac and non-cardiac, electronically-activated devices. Although the current literature provides data on the first generation of MR conditional cardiac pacemakers from multi-center trials conducted at research centers, post market data will be essential to assess impact of implementation of this technology in \"real world\" scenarios and provide long term data on the function of these systems \[[@B102],[@B141]\]. The impact of MR conditional pacemakers will also be dependent on implant rates of pacemakers versus ICDs, which vary by country \[[@B142]\]. Further research is required on multiple issues related to MRI interactions with devices, including, the effects of multiple scans on these systems and system effects at higher static magnetic field strengths \[[@B102]\]. The design, development, study and implementation of cardiovascular MR conditional devices will continue to require the expertise and collaboration of multiple disciplines and will need to prove safety, effectiveness and cost effectiveness in patient care.
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